BR112013018951A2 - formulações de testosterona - Google Patents

formulações de testosterona

Info

Publication number
BR112013018951A2
BR112013018951A2 BR112013018951A BR112013018951A BR112013018951A2 BR 112013018951 A2 BR112013018951 A2 BR 112013018951A2 BR 112013018951 A BR112013018951 A BR 112013018951A BR 112013018951 A BR112013018951 A BR 112013018951A BR 112013018951 A2 BR112013018951 A2 BR 112013018951A2
Authority
BR
Brazil
Prior art keywords
testosterone formulations
testosterone
formulations
Prior art date
Application number
BR112013018951A
Other languages
English (en)
Other versions
BR112013018951B1 (pt
Inventor
Grenier Arnaud
N Carrara Dario
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44146428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013018951(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of BR112013018951A2 publication Critical patent/BR112013018951A2/pt
Publication of BR112013018951B1 publication Critical patent/BR112013018951B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
BR112013018951-7A 2011-01-26 2012-01-18 Formulações transdérmicas ou transmucosais de testosterona e seu uso e kit que compreende pelo menos um recipiente que compreende uma formulação BR112013018951B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161436207P 2011-01-26 2011-01-26
US61/436,207 2011-01-26
EP11152210 2011-01-26
EP11152210.8 2011-01-26
PCT/EP2012/050695 WO2012101016A1 (en) 2011-01-26 2012-01-18 Testosterone formulations

Publications (2)

Publication Number Publication Date
BR112013018951A2 true BR112013018951A2 (pt) 2017-04-04
BR112013018951B1 BR112013018951B1 (pt) 2020-03-10

Family

ID=44146428

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013018951-7A BR112013018951B1 (pt) 2011-01-26 2012-01-18 Formulações transdérmicas ou transmucosais de testosterona e seu uso e kit que compreende pelo menos um recipiente que compreende uma formulação

Country Status (28)

Country Link
US (2) US8895053B2 (pt)
EP (2) EP2667851B1 (pt)
JP (2) JP6012632B2 (pt)
KR (1) KR101877476B1 (pt)
CN (1) CN103327962B (pt)
AR (1) AR085090A1 (pt)
AU (1) AU2012210691B2 (pt)
BR (1) BR112013018951B1 (pt)
CA (1) CA2824941A1 (pt)
DK (2) DK3072505T3 (pt)
ES (2) ES2741744T3 (pt)
HK (1) HK1192719A1 (pt)
HR (2) HRP20160887T1 (pt)
HU (3) HUE044327T2 (pt)
IL (1) IL227454A (pt)
JO (1) JO3755B1 (pt)
LT (2) LT3072505T (pt)
MX (1) MX340259B (pt)
PL (2) PL3072505T3 (pt)
PT (2) PT3072505T (pt)
RS (2) RS59012B1 (pt)
RU (1) RU2613891C2 (pt)
SA (1) SA112330224B1 (pt)
SI (2) SI2667851T1 (pt)
TR (1) TR201909271T4 (pt)
TW (1) TWI564029B (pt)
WO (1) WO2012101016A1 (pt)
ZA (1) ZA201305665B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
KR101795643B1 (ko) * 2009-05-01 2017-11-09 훼링 비.브이. 전립선암 치료용 조성물
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
EP2632934B1 (en) 2010-10-27 2016-11-30 Ferring B.V. Process for the manufacture of degarelix and its intermediates
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CA2874927A1 (en) 2012-06-01 2013-12-05 Gregoire Schwach Manufacture of degarelix
US8785426B1 (en) * 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
CN107949389A (zh) * 2015-09-30 2018-04-20 富士胶片株式会社 经皮吸收用组合物
US20200330371A1 (en) * 2017-10-30 2020-10-22 Teikoku Seiyaku Co., Ltd. Transdermally administrable preparation
US11523994B2 (en) 2018-01-10 2022-12-13 Celista Pharmaceuticals Llc Testosterone transdermal spray with film
CN109700764B (zh) * 2019-02-20 2021-07-06 广东食品药品职业学院 双氢睾酮原位凝胶喷雾剂及其制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2862341D1 (en) 1977-12-26 1983-11-24 Ihara Chemical Ind Co Process for producing aromatic monocarboxylic acid
WO1992019651A1 (en) 1991-04-25 1992-11-12 Romano Deghenghi Luteinizing hormone releasing hormone antagonist peptides
DK0556034T4 (da) 1992-02-12 2004-11-15 Daikyo Gomu Seiko Kk Et medicinsk instrument
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5925730A (en) 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5821230A (en) 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
DE10107663B4 (de) * 2001-02-19 2004-09-09 Lts Lohmann Therapie-Systeme Ag Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
GB0117057D0 (en) 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
AR042815A1 (es) 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
CN1997357A (zh) * 2003-03-11 2007-07-11 安塔雷斯制药Ipl股份公司 透皮或透粘膜应用活性剂的用途和制剂
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
AU2004283431B2 (en) * 2003-10-10 2009-09-10 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
EP1634583A1 (en) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2007124250A2 (en) * 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
CA2610708C (en) * 2005-06-03 2013-10-08 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
CA2623477C (en) * 2007-03-23 2011-05-31 Robert E. Dudley Compositions and method for treating pediatric hypogonadism
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
ES2589322T3 (es) 2008-02-11 2016-11-11 Safety Syringes, Inc. Jeringa con protector de seguridad de aguja y clip para evitar la liberación del protector durante un proceso de reconstitución
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
KR101795643B1 (ko) 2009-05-01 2017-11-09 훼링 비.브이. 전립선암 치료용 조성물
TW201043221A (en) 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
US20120046264A1 (en) * 2010-08-17 2012-02-23 Biosante Pharmaceuticals, Inc. Commercial scale production methods for transdermal hormone formulations
EP2632934B1 (en) 2010-10-27 2016-11-30 Ferring B.V. Process for the manufacture of degarelix and its intermediates
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CN103841970A (zh) 2011-07-15 2014-06-04 辉凌公司 其中施用匹可硫酸盐组合物的结肠镜检查定时方法

Also Published As

Publication number Publication date
AU2012210691A1 (en) 2013-08-01
JP2017019819A (ja) 2017-01-26
TW201309341A (zh) 2013-03-01
SA112330224B1 (ar) 2015-02-22
RS54898B1 (sr) 2016-10-31
LT3072505T (lt) 2019-08-26
TR201909271T4 (tr) 2019-07-22
NZ613029A (en) 2014-03-28
EP3072505B1 (en) 2019-06-12
HK1192719A1 (zh) 2014-08-29
RU2013133082A (ru) 2015-03-10
DK3072505T3 (da) 2019-08-12
PT3072505T (pt) 2019-07-04
BR112013018951B1 (pt) 2020-03-10
HUE044327T2 (hu) 2019-10-28
ES2586122T3 (es) 2016-10-11
JO3755B1 (ar) 2021-01-31
EP2667851A1 (en) 2013-12-04
TWI564029B (zh) 2017-01-01
CN103327962A (zh) 2013-09-25
LTPA2018516I1 (lt) 2018-11-12
PL3072505T3 (pl) 2019-12-31
CN103327962B (zh) 2016-04-27
HRP20191216T1 (hr) 2019-10-18
WO2012101016A1 (en) 2012-08-02
RU2613891C2 (ru) 2017-03-21
KR20140041431A (ko) 2014-04-04
IL227454A0 (en) 2013-09-30
RS59012B1 (sr) 2019-08-30
ZA201305665B (en) 2014-03-26
HUS1800036I1 (hu) 2018-09-28
JP2014503565A (ja) 2014-02-13
US20130295166A1 (en) 2013-11-07
US20150110856A1 (en) 2015-04-23
AR085090A1 (es) 2013-09-11
PT2667851T (pt) 2016-07-26
PL2667851T3 (pl) 2017-01-31
SI2667851T1 (sl) 2016-07-29
HUE027453T2 (en) 2016-09-28
US8895053B2 (en) 2014-11-25
EP2667851B1 (en) 2016-05-18
HRP20160887T1 (hr) 2016-09-23
DK2667851T3 (en) 2016-07-25
JP6012632B2 (ja) 2016-10-25
SI3072505T1 (sl) 2019-08-30
EP3072505A1 (en) 2016-09-28
ES2741744T3 (es) 2020-02-12
MX2013008463A (es) 2013-10-03
HUE027453T4 (hu) 2018-12-28
KR101877476B1 (ko) 2018-07-11
MX340259B (es) 2016-07-04
CA2824941A1 (en) 2012-08-02
AU2012210691B2 (en) 2016-05-12
IL227454A (en) 2017-02-28

Similar Documents

Publication Publication Date Title
LTPA2018516I1 (lt) Testosterono kompozicijos
SMT201500054B (it) 2-Anilinobenzimidazolo-6-carbossammidi come agentianti-infiammattori
BR112013017183A2 (pt) composições de bepostatina
CO6930368A2 (es) Composiciones de yodo-povidona estable
CO6801637A2 (es) Formulaciones de anticuerpos
BR112014000879A2 (pt) deflegmador
CO6960543A2 (es) 2-tiopirimidinonas
BR112014000015A2 (pt) formulação
DE102011100082A8 (de) Traygreifvorrichtung
CO6960557A2 (es) Derivados de 2-yodo-imidazol
DK2729012T3 (da) Mælkebaseret formulering
DK2672817T3 (da) Forbedrede insekticide formuleringer
BR112013007492A2 (pt) glicodendrímeros de polipropileterimina
GB201110278D0 (en) Formulations
FR2967069B3 (fr) Formulations
DK2598472T3 (da) Formuleringer
DOS2011000357S (es) Cubitos de caldo (caldos)
ITMI20121127A1 (it) Sterilizzatore
ES1076205Y (es) Conjunto de sobredentadura
GB201111578D0 (en) Pharmeutical formulations
GB201111013D0 (en) Formulations
GB201107627D0 (en) Formulations
GB201107626D0 (en) Formulations
ES1075445Y (es) Cubierto
GB201105410D0 (en) Formulations

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/01/2012, OBSERVADAS AS CONDICOES LEGAIS.